SRSF2 and non-small cell lung carcinoma: Additionally, in the context of non-small cell lung cancer (NSCLC), the use of small molecule inhibitors like H3B-8800, targeting splicing events associated with mutations in splicing factors such as SRSF2, SF3B1, and U2AF1, represents a novel strategy to disrupt the splicing apparatus and attenuate the proliferation of neoplastic cells (35, 36).